# First-In-Human Study of Apramycin

> **NCT04105205** · PHASE1 · COMPLETED · sponsor: **Juvabis AG** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Apramycin injection
- **DRUG:** Placebo injection

## Key facts

- **NCT ID:** NCT04105205
- **Lead sponsor:** Juvabis AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-25
- **Primary completion:** 2020-07-16
- **Final completion:** 2020-10-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04105205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04105205, "First-In-Human Study of Apramycin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04105205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*